Film dosimetry studies for patient specific quality assurance in microbeam radiation therapy
Résumé
Highlights •A methodology has been developed for patient specific quality assurance in MRT. •The segmentation of peaks and valleys doses can be done on Gafchromic films for direct comparisons with MRT treatment plan. •Gamma-index tests performed on normalised dose distributions exhibit over 90% passing rate. •Some discrepancies remain on the absolute isocenter doses and require further investigation. •Despite these discrepancies, large animal MRT studies are starting at the ESRF based on valley doses prescription.AbstractMicrobeam radiation therapy (MRT) uses synchrotron arrays of X-ray microbeams to take advantage of the spatial fractionation effect for normal tissue sparing. In this study, radiochromic film dosimetry was performed for a treatment where MRT is introduced as a dose boost in a hypofractionated stereotactic radiotherapy (SRT) scheme. The isocenter dose was measured using an ionization chamber and two dimensional dose distributions were determined using radiochromic films. To compare the measured dose distribution to the MRT treatment plan, peak and valley were displayed in separate dosemaps. The measured and computed isocenter doses were compared and a two-dimensional 2%/2 mm normalized Math Eq-index analysis with a 90% passing rate criterion was computed. For SRT, a difference of 2.6% was observed in the dose at the isocenter from the treatment plan and film measurement, with a passing rate of 96% for the Math Eq-index analysis. For MRT, peak and valley doses differences of 25.6% and 8.2% were observed, respectively but passing rates of 96% and 90% respectively were obtained from the normalized Math Eq-index maps. The differences in isocenter doses measured in MRT should be further investigated. We present the methodology of patient specific quality assurance (QA) for studying MRT dose distributions and discuss ideas to improve absolute dosimetry. This patient specific QA will be used for large animal trials quality assurance where MRT will be administered as a dose boost in conventional SRT. The observed remaining discrepancies should be studied against approximations in the TPS phantom materials, beams characteristics or film read-out procedures.
Origine | Fichiers produits par l'(les) auteur(s) |
---|